Arcturus Therapeutics Holdings (ARCT) Operating Leases (2019 - 2025)
Historic Operating Leases for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Q3 2025 value amounting to $21.9 million.
- Arcturus Therapeutics Holdings' Operating Leases fell 1586.18% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year decrease of 1586.18%. This contributed to the annual value of $25.0 million for FY2024, which is 350.87% down from last year.
- According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' Operating Leases is $21.9 million, which was down 1586.18% from $22.9 million recorded in Q2 2025.
- In the past 5 years, Arcturus Therapeutics Holdings' Operating Leases ranged from a high of $32.2 million in Q2 2022 and a low of $4.1 million during Q1 2022
- Its 5-year average for Operating Leases is $21.2 million, with a median of $25.9 million in 2023.
- Per our database at Business Quant, Arcturus Therapeutics Holdings' Operating Leases tumbled by 2894.92% in 2022 and then soared by 61942.32% in 2023.
- Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Operating Leases stood at $4.5 million in 2021, then soared by 571.17% to $30.2 million in 2022, then decreased by 14.26% to $25.9 million in 2023, then fell by 3.51% to $25.0 million in 2024, then decreased by 12.53% to $21.9 million in 2025.
- Its Operating Leases was $21.9 million in Q3 2025, compared to $22.9 million in Q2 2025 and $24.0 million in Q1 2025.